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Bioavailability and feasibility of subcutaneous 5-fluorouracil
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Summary Continuous intravenous (i.v.) infusion of 5-fluorouracil (5-FU) has been shown to be superior to
bolus regimens in terms of response rates and toxicity. However, a continuous infusion is more expensive and
prone to complications such as thromboembolism and infections. A way to circumvent these problems would
be to administer 5-FU subcutaneously (s.c.). To assess feasibility and bioavailability of s.c. 5-FU, eight
patients with advanced cancer received 250 mg 5-FU as an infusion over 90 min either intravenously (i.v.) or
s.c. into the abdominal wall. The mean ± s.d. bioavailability of s.c. 5-FU was 0.89 ± 0.23. The interpatient
variability for the area under the plasma concentration-time curve was 48% for the s.c. and 36% for the i.v.
infusion. No local side effects were observed. To test the local tolerance of a more prolonged administration
three patients received 930-1,000 mg m2 5-FU by 24-h continuous s.c. infusion. The steady-state plasma
levels were comparable to i.v. infusion. One patient developed a painless skin pigmentation at the s.c. infusion
site. However, the same reaction was observed at the forearm after i.v. infusion. We conclude that at the dose
studied s.c. 5-FU has an almost complete bioavailability and is well tolerated. Further work will show,
whether prolonged s.c. infusion can be used as a safe and economical alternative to i.v. infusion.
Since its discovery some 30 years ago, 5-fluorouracil (5-FU)
has remained a cornerstone in the treatment of a variety of
solid tumours such as gastrointestinal, breast, and head and
neck carcinomas. However, the ideal treatment schedule has
still to be defined (Bruckner & Motwani, 1991). The short
half-life of the drug and its cell cycle phase-specific action
favour prolonged infusion. This is supported by promising
response rates of trials using high-dose 4- to 5-day or lower-
dose multiweek infusions in the treatment of colorectal and
head and neck tumours (Seifert et al., 1975; Al-Sarraf, 1988;
Lokich et al., 1989; Dreyfuss et al., 1990). In addition,
significantly less hematological and gastrointestinal side
effects are seen with continuous infusion compared to bolus
regimens (Lokich et al., 1989; Macdonald, 1989).
Disadvantages of continuous intravenous 5-FU are in-
convenience, costs, and the potential complications of a
permanent catheter. High-dose continuous 5-FU requires
hospitalisation in most of the cases. Other expenses arise
from the pump, the catheter, and its placement (Hansen et
al., 1989; Macdonald, 1989). These start-up costs become
more relevant for patients with a limited life expectancy
which are no exception among the target group for this
treatment. Permanent catheter systems are prone to infec-
tions, dislocation and clotting. These complications occurred
in five of 22 patients in a study which compared inpatient
and outpatient treatment and lead to catheter replacement in
four patients (Vokes et al., 1989).
Subcutaneous continuous administration circumvents the
need for an intravenous catheter or hospitalisation. The
studies by Cerny et al. with prolonged s.c. ifosfamide and
cyclophosphamide demonstrate a good feasibility and bio-
availability and patients prefer this way of administration to
the intravenous infusion (Cerny et al., 1990; Cerny et al.,
1991). This experience lead us to the present study which
clearly encourages further work with s.c. 5-FU administra-
tion.
Methods
Patients
Eleven ambulatory patients (see Table I) with advanced
cancer gave oral consent to participate in this study, which
was approved by the ethics committee of the institution.
5-FU administration and blood sampling for the study were
performed before the start of a regular chemotherapy cycle
with 5-FU or other drugs. Normal serum creatinine, serum
bilirubin <50tsmol 1-1, and a complete blood cell count
which did not interfere with full 5-FU dose administration
were required. Some samples of patients BeH and RF were
not measured because of processing errors. These patients
could not be included in the calculation of the bioavailability
of s.c. 5-FU.
Drug administration
Two hundred and fifty mg 5-FU (F.Hoffmann-La Roche
Ltd., Basel, Switzerland) was diluted 1:1 (volume:volume)
with sterile water to a final volume of 10 ml and administered
over 90 min either subcutaneously (s.c.) or intravenously
(i.v.). A portable gas-driven disposable syringe infusor
(Dysetronic® Infusor, Dysetronic AG, Burgdorf, Switzerland)
did provide a constant infusion pressure of about 1.1 bar
with a safety valve set at 2 bar. The same type of catheter
(Venflon 2,18 G/1,2 mm O.D., length 45 mm; Viggo Prod-
ucts, Helsingborg, Sweden) was used for s.c. and i.v.
infusions. For s.c. use the catheter was placed in the paraum-
bilical abdominal wall without anaesthesia. The site of
infusion was covered with a sterile transparent adhesive
plaster to allow observatin of skin alterations. Three patients
received 930- 1,000 mg m-2 5-FU by 24-h continuous s.c.
infusion to test the local tolerance of a prolonged infusion.
Collection ofbloodsamples and analytical method
Venous blood samples (5 ml) were collected in containers
with EDTA at time 0 (predose), 15, 30, 50, 70, 90, 110, 130,
Table I Patient characteristics
Age BSAa
Patient Sex (years) Primary tumour (m2)
AA m 61 Lung (NSCLCb) 1.7
BA m 50 Lung (NSCLCb) 2.0
BH m 41 Rectum 2.0
BeH m 70 Colon 1.8
BM f 61 Colon 1.5
BV f 62 Ovary 1.7
HL f 63 Breast 1.9
ME m 61 Stomach 1.8
MH m 68 Head and neck 1.8
RF f 60 Colon 1.6
SA m 63 Pancreas 2.1
aBody surface area. bNon small-cell lung cancer.
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150, 180, 240 (min). Samples were centrifuged (3,000 x g) for
10 min and frozen (- 20°C) until analysed.
5-FU in plasma was analysed by using a high-performance
liquid chromatographic method that involved liquid-liquid
extraction/backextraction, reversed phase chromatography
and UV detection (Stetson et al., 1985). The lower limits of
detection and quantification (with 5-chlorouracil for internal
standardisation) in 1 ml of plasma were 10 and 20 ng ml-',
respectively. The standard curve was linear (r>0.992)
between 20 and 2,400 ng ml'. Interassay reproducibilities
were 5.1, 6.7 and 3.4% (n = 8, each) with 78, 260 and
780 ng ml-' control specimens which were used simul-
taneously with each assay batch. The corresponding precision
data were 102.3, 100.6 and 97.4%, respectively.
Kinetic analysis
The bioavailability (F) was calculated by dividing the area
under the plasma concentration-time curve (AUC) following
s.c. 5-FU by the AUC following i.v. administration assuming
a constant clearance. The 5-FU clearance has been described
to be half-saturated (Km) at a concentration of 15 LM
(1.95 tg ml-') (Collins et al., 1980). Although it is not to be
expected that this 5-FU concentration would be reached with
250 mg 5-FU/90 min, it cannot be excluded that factors such
as the presence of liver metastases might lower the actual Km
value in a given patient. The AUC was obtained by using the
trapezoidal rule.
Results
The bioavailability of s.c. 5-FU in eight patients varied
between 0.60 and 1.28 with a mean value of 0.89 ± 0.23
(Table II). The s.c. administration showed a only slightly
higher interindividual variability of the AUC than the i.v.
administration (coefficient of variation 48% vs 36%).
For most of the patients the steady-state concentration was
not reached during the relatively short infusion period
because of the protracted release of 5-FU from the s.c. site to
the central vascular compartment. In three patients (AA, BA,
SA) the plasma concentration-time curve reached a plateau
after 0.5, 0.82, and 0.87 h, respectively. Figure 1 shows the
plasma concentration-time curve of patient HL which is vir-
tually identical to the summation curve of all patients (not
shown). The fact that the blood levels start falling before the
end of the infusion in some patients might be explained by
an irregularity of the pump flow rate.
All patients tolerated the s.c. infusion without local side
effects such as pain, other sensations, infection, inflam-
mation, or pigmentation. The infusion site was checked at
least twice daily for the first 2 days, thereafter at least
weekly. Three patients (BM, MH, RF), which were treated
with continuous i.v. 5-FU, accepted to receive one 24 h dose
s.c. to assess the local tolerance of a prolonged infusion.
Table II Pharmacokinetic parameters after s.c.
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Figure 1 Representative plasma concentration time curve after
s.c. ( O-) and i.v. (- *) infusion of 250mg 5-FU over
90 min (patient HL).
Blood for steady-state drug concentration measurements was
drawn during the last hour of the infusion. The kinetic data
of the prolonged s.c. infusion are summarised in Table III.
Patient RF developed a painless local skin pigmentation and
later desquamation. However, a similiar skin reaction was
observed at the catheter site (arm) following the next intra-
venous infusion.
Discussion
5-FU is an important component in the treatment of a
variety of solid tumours. In colorectal cancer 5-day high-dose
or prolonged (several weeks) continuous low-dose infusion
have shown higher response rates and were better tolerated
than standard 5-day monthly bolus regimen (Seifert et al.,
1975; Lokich et al., 1989). In head and neck cancer the most
potent drug combinations include continuous 5-FU (Kish et
al., 1984; Dreyfuss et al., 1990) which was superior to bolus
Table III Pharmacokinetic parameters after s.c. or i.v. infusion of
indicated 5-FU dose over 24 h
Steady-state concentration
(ngml-')
Patient Daily dose s.c. i.v.
BM 1500 mg 166 112
MH 1750 mg 176 190
RF 1500 mg 403 531
and i.v. infusion of 250 mg 5-FU over
Area under the curve Peak concentration Steady-state
(ng h ml-') (ng ml-') concentration
Patient s.c. i.v. Bioavailability s.c. i.v. (ngml-')
AA 234 285 0.82 163 296 150
BA 398 600 0.66 215 501 203
BH 715 557 1.28 523 615
BeH * 777 * * 567
BM 892 928 0.96 750 757
BV 1040 1070 0.97 683 855
HL 582 795 0.73 575 587
ME 1075 1009 1.07 682 840
RF 1070 * * 545 *
SA 306 511 0.60 204 465 193
*not done.
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administration (Kish et al., 1985). Finally, a fraction of
breast cancer patients refractory to 5-FU-containing com-
binations still responds to a prolonged low-dose infusion of
5-FU alone (Huan et al., 1989). In most of these situations
the therapy has mainly palliative intent. Costs, the complica-
tions of a permanent catheter, and in some situations the
need for hospitalisation are disadvantages of prolonged i.v.
infusion. However, these problems are circumventable by s.c.
drug administration (Cerny et al., 1990; Cerny et al., 1991).
Not surprisingly, ambulatory treatment is preferred by most
patients (Vokes et al., 1989; Cerny et al., 1990; Cerny et al.,
1991).
Our results show that s.c. 5-FU has an almost complete
bioavailability (mean: 89%). For the calculation of the
bioavailability a constant clearance has been assumed. How-
ever, as pointed out earlier it is known that the clearance of
5-FU is saturable (Collins et al., 1980). We chose a relatively
high dose rate of 5-FU (250 mg /1.5 h) to increase the chance
to be well above the detection limit also in case of poor s.c.
absorption. Thus it is possible that the actual clearance of the
s.c. infusion was higher compared to the i.v. infusion. The
results from three patients which received a 24-h s.c. infusion
seem to show a good absorption from the s.c. administration
site also over an extended time period.
Flaws of our pharmacokinetic analysis are the short
infusion duration without reaching the steady-state concen-
tration in most of the patients and irregularities of the pump
flow, which lead to the premature run out of the infusion in
some cases. However, the goal of this study, to assess
bioavailability and feasibility of s.c. 5-FU, should not have
been hampered by these factors.
The tolerability of the s.c. infusion was satisfactory. One
patient (RF) which reacted to the 24-h infusion with painless
local skin pigmentation and desquamation, showed the same
reaction at the forearm after intravenous infusion. Thus, this
side effect cannot be attributed to the mode of 5-FU admini-
stration.
We conclude that s.c. 5-FU is well tolerated and has a
good bioavailability. Before accepting this way of administra-
tion as equivalent to the i.v. infusion, it should be shown that
these favourable characteristics are maintained over a pro-
longed treatment period.
The authors wish to express their thanks to Liselotte Dietrich and all
the nurses involved for their expertise, initiative, and dedicated
patient care.
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